Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAd-COV2 COVID-19 vaccine Phase II/III trial in adults
2020-005915-39Phase 2Completed
- Sponsor
- ReiThera
- Start
- Mar 2021
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing GRAd-COV2 vaccine with Placebo (2 arms). Primary endpoint: Primary endpoints Phase II. Started Mar 2021; status: completed.
02
Drugs
GRAd-COV2
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005915-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005915-39.